83 results about "Sitagliptina" patented technology

The invention discloses aminotransferase, a mutant and application to Sitagliptin preparation. According to the application, wet thalli obtained by performing fermentation culture on recombinant escherichia coli containing aminotransferase encoding genes are used as biocatalysts; Sitagliptin precursor ketone is used as a substrate; dimethyl sulfoxide is used as a latent solvent; phosphopyridoxal is used as a coenzyme; isopropylamine is used as an auxiliary substrate; a trolamine buffer solution with the pH being 8 to 9 is used as a reaction medium; a reaction system is formed; the biocatalytic reaction is performed under the conditions of the temperature being 30 to 45 DEG C and the stirring speed being 100 to 250 r/min; after the reaction is completed, the reaction liquid is separated and purified; the Sitagliptin is obtained. The aminotransferase and the mutant are used as biocatalysts; the latent carbonyl compound of Sitagliptin precursor ketone is directly used as the substrate; meanwhile, biocatalytic reaction is performed by using isopropylamine as the auxiliary substrate and using the pyridoxal phosphate as the coenzyme; the separation and purification is performed; Sitagliptin with high optical purity is prepared. The method has the advantages that the total yield is 76 percent; the product e.e. value reaches 99 percent.

The invention discloses an aspartase mutant, which comprises the following mutations M321V, K324T and N326S on an amino acid sequence represented by SEQ ID NO.2, and has high enzymatic activity compared with wild-type aspartase in catalysis of (E)-4-(2,4,5-trifluorophenyl)2-butenoic acid. The invention also discloses applications of the aspartase mutant in preparation of (R)-3-amino-4-(2,4,5-trifluorophenyl)-butyric acid. According to the invention, with the application of the aspartase mutant in an enzyme catalytic reaction to prepare a sitagliptin chiral intermediate (R)-3-amino-4-(2,4,5-trifluorophenyl)-butyric acid, the conversion rate is high, the stereoselectivity is high, the yield is high, the production cost is low, the environment is friendly, and industrial large-scale production is facilitated.

The invention provides a preparation method of sitagliptin. The preparation method comprises the following steps of: performing condensation reaction on hydrochloride of 3-trifluoromethyl-[1,2,4] triazol [4,3-a] piperazine serving as a starting raw material and methyl malonyl chloride under a normal temperature condition; reacting an obtained product with 2,4,5-trifluorophenylacetic acid under an alkaline condition and then performing condensation reaction with (S)-phenylglycinamide under normal temperature condition to obtain a product; reducing the obtained product through a reducing agent; removing an ester group through heating reflux; and reacting with a hydrogenation reducing reagent to obtain the sitagliptin. The preparation method has the advantages of low cost, high yield, easiness in operation, all used reagents of conventional reagents, simple post-treatment and convenience for industrial production.

The invention relates to a reagent for detection of biological activity of glucagon-like peptide-1 (GLP-1). The reagent added into each 15 microliters of a detection sample comprises: 1, 35-45 microliters of a membrane reaction solution, 2, 15-25 microliters of a GLP-1 acceptor, 3, 10-20 microliters of a GLP-1 standard substance, 4, 5-15 microliters of sitgliptin phosphate, 5, 1-10 microliters of triphosadenine, 6, 1-10 microliters of guanosine triphosphate, 7, 5-15 microliters of 3-isobutyl-1-methylxanthine, 8, 1-10 microliters of bovine serum albumin, 9, 50-150 microliters of a biotin-labeled mouse anti-human cAMP monoclonal antibody, 10, a microwell plate coated with a goat anti-human cAMP polyclonal antibody, 11, 50-150 microliters of an avidin-labeled horseradish peroxidase, 12, 300-400 microliters of a PBS washing liquor, 13, 50-150 microliters of a chromogenic substrate, and 14, 50-150 microliters of a stop buffer. The GLP-1 acceptor is produced by genetic recombination, is convenient for purification and can reduce the batch difference of the reagent. The GLP-1 acceptor is used as a probe for capturing GLP-1 so that detection sensitivity is improved, biological activity can be directly determined, sensitivity is high, and practicality is strong.

The invention discloses preparation methods for sitagliptin intermediates including 3-carbonyl-4-(2,4,5-trifluorophenyl)-butyrate (I) and 1-(3-trifluoromethyl-5,6-dihydro-8H-(1,2,4) triazole-(4,3-a) pyrazine-7-)-4-(2,4,5-trifluorophenyl)-1,3-butanedione (II). The preparation method for the intermediate (I) includes the steps of preparing corresponding Grignard reagent by bromoacetate and magnesium powder by means of Grignard reaction, and preparing the intermediate I by means of addition reaction between the Grignard reagent and 2,4,5-trifluoro-benzeneacetonitrile. The preparation method for the intermediate (II) includes the steps of carrying out acylation reaction between bromoacetic acid and III under the action of condensing agent so that IV is prepared, carrying out Grignard reaction between the IV and magnesium powder so that corresponding Grignard reagent V is prepared, and finally preparing the intermediate (II) via addition reaction between the Grignard reagent V and 2,4,5-trifluoro-benzeneacetonitrile in organic solvent. The preparation methods for the sitagliptin intermediates are mild in reaction conditions, simple and convenient in operation and available in raw materials and have excellent industrialized prospect.

The invention discloses an amine transaminase AcATA mutant and application of the amine transaminase AcATA mutant in preparation of a sitagliptin intermediate. The amine transaminase AcATA mutant is obtained by single mutation at the 122th site of an amino acid sequence shown in SEQ ID No.2. The amino acid sequence of the amine transaminase AcATA mutant is shown in SEQ ID No.2. The amino acid sequence of the amine transaminase AcATA mutant is shown in the description, wherein methionine at the 122 position is mutated into histidine, valine or phenylalanine. According to the invention, sites possibly influencing the catalytic activity are obtained through molecular docking, homologous modeling and other methods, and site-specific mutagenesis is carried out, so that the finally obtained aminotransferase AcATA mutant has high enzyme activity, and the enzyme activity is higher than 460U/g and is more than 4 times of that of a wild type; the catalyst can efficiently catalyze the sitagliptin intermediate precursor ketone 1-piperidine-4-(2, 4, 5-trifluorophenyl)-1, 3-dibutanone to synthesize the sitagliptin intermediate (R)-3-amino-1-piperidine-4-(2, 4, 5-trifluorophenyl)-1-butanone, and the 24-hour conversion rate is up to 90%.

The invention discloses a (R)-omega-transaminase mutant and application thereof. The mutant is obtained by multi-point mutation of leucine at 182, arginine at 79, glutamine at 51, valine at 149, leucine at 235 and glycine at 216 in an amino acid sequence shown by SEQ ID NO.1. New (R)-omega-TA enzyme is screened through a gene mining technology in the invention; furthermore, molecular modificationis carried out through a protein engineering technology; a (R)-omega-TA mutant catalysis having high enzyme activity, high substrate tolerance and high stereoselectivity is obtained; the mutant can biologically catalyze precursor ketone analogue 1-(3-oxygen pyrrolidine-1-yl)-4-(2,4,5-trifluorophenyl)-1,3-butanedione synthesis sitagliptin intermediate (R)-1-[3-amino-4-(2,4,5-trifluorophenyl) butyryl] pyrrole-3-ketone; furthermore, the conversion rate is relatively high; the conversion rate can be up to 95.4%; and thus, the (R)-omega-transaminase mutant and application thereof in the invention have milestone meaning for breaking through a sitagliptin biocatalysis preparation technology.

The invention discloses a transaminase mutant and application thereof in preparation of sitagliptin intermediate. The transaminase mutant is prepared by substituting tyrosine at locus 74 with proline,glutamic acid at locus 228 with aspartic acid, leucine at locus 254 with alanine and methionine at locus 290 with threonine in an amino acid sequence shown as SEQ ID NO: 2. According to the application of the transaminase mutant in the preparation of the sitagliptin intermediate, the sitagliptin intermediate is prepared by a method which takes wet thallus or pure enzyme obtained by fermenting andculturing engineering bacteria containing transaminase mutant encoding genes as a biocatalyst, as well as a sitagliptin intermediate precursor ketone or a prochiral carbonyl compound as a substrate.The total yield of the method is about 82%; and the e.e. value of the product can be up to 99%.

The invention discloses a (R)-omega-transaminase mutant and an application thereof in preparation of a sitagliptin intermediate. The mutant is obtained through multipoint mutation of arginine at the 77th site, leucine at the 181st site, arginine at the 130th site, tyrosine at the 139th site and threonine at the 273th site of an amino acid sequence shown as SEQ ID NO.1. According to the invention,a novel (R)-omega-TA recombinase is screened through a gene mining technology; molecular modification is carried out through a protein engineering technology; an (R)-omega-TA mutant catalyst with highenzyme activity, high substrate tolerance and high stereoselectivity is obtained; and the mutant can be used for asymmetric catalytic synthesis of the sitagliptin intermediate (R)-3-amino-1-(pyrrolidine-1-yl)-4-(2, 4, 5-trifluorophenyl) butan-1-one by taking a precursor ketone analogue 1-(pyrrolidine-1-yl)-4-(2, 4, 5-trifluorophenyl)-1, 3-butanedione as a substrate, and has higher conversion rate.

The invention provides application of immobilized transaminase in preparation of sitagliptin and/or (R)-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone. The immobilized transaminase comprises resin and a transaminase mutant, wherein the amino acid sequence of the transaminase mutant is shown as SEQ ID NO. 3 or SEQ ID NO. 7. The invention also provides the immobilized transaminase, a transaminase mutant and a preparation method and application of the immobilized transaminase and the transaminase mutant. The transaminase mutant is very high in enzyme activity when catalyzing a ketoamide substrate; the enzyme activity is still very high after the transaminase mutant is made into immobilized transaminase; and when the transaminase mutant is used for catalyzing a ketoamide substrate to produce sitagliptin or an intermediate thereof, a screened solvent reaction system is combined, and the immobilized transaminase is high in conversion rate, good in stereoselectivity, good in stability, higher in reusability and simpler to operate, so production cost is reduced, and industrial production is facilitated.

The invention relates to the technical filed of organic chemistry, in particular to an intermediate for preparing Sitagliptin and a preparation method and application of the intermediate. The structure of the intermediate is as shown in a formula A (Please see the formula A in the description.), wherein R adopts hydrogen or a formula as shown in the description.

The invention relates to recombinant R-omega-transaminase, a mutant and an application of the recombinant R-omega-transaminase and the mutant in asymmetric synthesis of sitagliptin. According to the invention, novel R-omega-transaminase is screened and recombined with the existing high-efficiency transaminase; the amino acid sequence of the obtained recombinant is shown as SEQ ID: 15, and the mutant thereof is obtained by carrying out single-site mutation or multi-site mutation on one or more of 71, 135 and 292 amino acid sequences shown in SEQ ID: 15; the optimal amino acid sequence of the R-omega-transaminase mutant strain is shown as SEQ ID: 17; and the corresponding nucleotide sequence is shown as SEQ ID: 18. The invention provides the R-omega-TA mutant with higher activity (582.4U/g) and stereoselectivity (e.e.value 99.9%). A 500mM substrate can be catalyzed to be converted into sitagliptin, and the conversion rate is as high as 99%. The mutant has an important significancefor improving the sitagliptin biocatalytic preparation technology.

Disclosed is a method for synthesizing a sitagliptin intermediate, the method comprising: in the presence of hydrogen and a transition metal catalyst having a chiral phosphine ligand, subjecting a compound of formula II to an asymmetric reductive amination with ammonia or ammonium salt in a proper organic solvent under the condition of adding an acidic additive to produce a compound of formula I, wherein, an R- or S-configuration of a stereocenter is represented by *; the compound of formula I of R configuration can be used to prepare sitagliptin, and a reaction formula is as follows: R¹ and R² are each independently selected from hydrogen, C₁-C₁₂ linear or branched alkyl, C₃-C₁₂ cycloalkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl and C₇-C₁₂ arylalkyl. The method has a high yield and a high ee % value, a mild reaction condition and a low production cost, and is simple to operate, convenient to purify, environmental friendly and suitable for industrial production.

The invention discloses a preparation method of a sitagliptin intermediate. The preparation method of the sitagliptin intermediate comprises the following step: in a solvent, carrying out a reaction as shown in the specification on a compound as shown in a formula 2 and a compound as shown in a formula 3 to obtain a compound as shown in a formula 4. The preparation method is high in yield, avoids the use of explosive reagents and phosphorus oxychloride, and is suitable for industrial production.

The invention discloses a preparation method of a sitagliptin intermediate and the sitagliptin intermediate prepared by the preparation method, the preparation method comprises the step that in the presence of an organic solvent with a boiling point not higher than 110 DEG C at a standard atmospheric pressure, carrying out transamino contact between transaminase and a substrate sitagliptin precursor ketone (2Z)-4-oxo-4-[3-(trifluoromethyl)-5, 6-dihydro-[1, 2, 4]triazolo[4, 3-a]pyrazine-7-(8H)-yl]-1-(2, 4, 5-trifluorophenyl) butyl-2-one to perform enzyme catalysis reaction so as to prepare the sitagliptin intermediate (3R)-3-amino-1-[3-(trifluoromethyl)-5, 6, 7, 8-tetrahydro-1, 2, 4-triazolo [4, 3-a] pyrazine-7-yl]-4-(2, 4, 5-trifluorophenyl) butyl-1-one, a mixed solution obtained by mixing a low-boiling-point organic solvent and the substrate is added into a premixing system containing the transaminase in a fed-batch mode, ketoreductase and a coenzyme regeneration system in a specific proportion are added into the premixing system, the substrate conversion rate is increased, and the substrate conversion rate can reach 99%.

The invention relates to a green synthesis method of a sitagliptin intermediate, and belongs to the technical field of drug intermediate synthesis. In order to solve the problems of serious pollution and instability in the prior art, the invention provides a green synthesis method of a sitagliptin intermediate, which comprises the following steps: reacting ethyl trifluoroacetate with ethylene diamine in an ether solvent to generate 2-trifluoroacetamido ethyl amine; in the presence of an acid-binding agent, carrying out condensation reaction on 2-trifluoroacetamido ethyl amine and halogenated ethyl acetate at the temperature of 45-65 DEG C to generate an intermediate, then heating to 90-110 DEG C, and carrying out cyclization reaction to generate N-trifluoroacetyl piperazinone; carrying out reaction on N-trifluoroacetyl piperazinone and hydrazine hydrate to generate 1-trifluoroacetyl hydrazino-2-piperazinone; and reacting the intermediate with hydrochloric acid to carry out internal ring formation and salt formation reaction to obtain the product sitagliptin intermediate. According to the invention, the reaction has the advantages of high product yield and purity on the whole, and is environment-friendly.

The invention belongs to the technical field of medicinal preparations and particularly relates to a medicinal composition for treating diabetes and obesity and preparation and use thereof. The invention is characterized in that the active ingredient of a single dose of medicine comprises 10 to 90 milligrams of Sitagliptin or salt thereof based on Sitagliptin and 5 to 50 milligrams of Simvastatin or Lovastatin, preferably 25 to 50 milligrams of Sitagliptin or salt thereof and 5 to 25 milligrams of Simvastatin or Lovastatin. The medicinal composition can be prepared into any formulation acceptable in pharmaceutics, preferably oral solid preparation.

The invention discloses transaminase and application thereof in preparation of sitagliptin. The amino acid sequence of the transaminase is shown as SEQ ID NO: 1, or the amino acid sequence of the transaminase is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% similar to the SEQ ID NO: 1. The transaminase can asymmetrically catalyze sitagliptin precursor ketone (2Z)-4-oxo-4-[3- (trifluoromethyl)-5, 6-dihydro-[1, 2, 4] triazolo [4, 3-a] pyrazine-7-(8H)-yl]-1-(2, 4, 5-trifluorophenyl) butyl-2-ketone to generate sitagliptin intermediate (3R)-3-amino-1-[3-(trifluoromethyl)-5, 6, 7, 8-tetrahydro-1, 2, 4-triazolo [4, 3-a] pyrazine-7-yl]-4- (2, 4, 5-trifluorophenyl) butyl-1-ketone, the enzyme activity of the transaminase can reach 1100U/g, and when an enzymatic reaction is carried out for 2h, 50 microliters of transaminase liquid can make the substrate conversion rate reach 55%. Compared with existing transaminase for catalyzing the same reaction, the transaminase has the advantages of high activity, ideal stability and good organic solvent tolerance.